Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes |
AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.12 | KE:1281 | Increased, DNA Damage-Repair |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.2 | KE:1393 | Hepatocytotoxicity |
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.2 | KE:155 | Inadequate DNA repair |
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.2 | KE:155 | Inadequate DNA repair |
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.09 | KE:155 | Inadequate DNA repair |
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.1 | KE:155 | Inadequate DNA repair |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.1 | KE:155 | Inadequate DNA repair |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.5 | KE:885 | Increase, Cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.29 | KE:1556 | Increase, lung cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.11 | KE:1193 | N/A, Breast Cancer |
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.11 | KE:1193 | N/A, Breast Cancer |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.14 | KE:1670 | Lung cancer |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1670 | Lung cancer |
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.2 | KE:1670 | Lung cancer |
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:1670 | Lung cancer |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.11 | KE:1670 | Lung cancer |
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.09 | KE:2034 | liver dysfunction |
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.17 | KE:885 | Increase, Cancer |
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous System Disease | Under Development | 0.11 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.25 | KE:786 | Increase, Cytotoxicity (hepatocytes) |
AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor |
AOP:545 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | Unclassified | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:548 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression | Unclassified | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.